Stage C or not stage C…? by Claire Dearden Blood

Slides:

Advertisements

Similar presentations

RNA interference in biology and disease by Carol A. Sledz, and Bryan R. G. Williams Blood Volume 106(3): August 1, 2005 ©2005 by American Society.

Advertisements

Functional Analysis of the Neurofibromatosis Type 2 Protein by Means of Disease- Causing Point Mutations Renee P. Stokowski, David R. Cox The American.

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Investigating a New Methodology for the Detection of Low Frequency 17p Deleted Clones in Chronic Lymphocytic Leukaemia (CLL): Impact on Prognostic Outcome.

Patient Controlled Analgesia (PCA)

Hyperbaric Oxygenation in Cardiac and Pulmonary Disease

MBL: mostly benign lymphocytes, but…

VEGF therapy: risky business for established plaques?

Defects in DBA: more than meets the eye

by James O. Armitage, and Dan L. Longo

Gupta V, Tallman MS, Weisdorf DJ

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

by Zhenping Zhu Blood Volume 108(6): September 15, 2006

BTK inhibition in myeloma: targeting the seed and the soil

Mohamed A. Kharfan-Dabaja, Claudio Anasetti, Edgardo S. Santos

Tax fingerprint in adult T-cell leukemia

One giant leap for pediatric AMKL

Critiquing Cryos by Morie Gertz Blood Volume 111(11):

Nonmyeloablative conditioning for relapsed follicular lymphoma

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Fluorescent neutrophils throw the spotlight on inflammation

by Ernest Beutler Blood Volume 98(9): November 1, 2001

An actuarial GPS for hemophilic longevity

Taking a leaf from the book of oral tolerance

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors Kenneth.

How I treat refractory CLL

Anergy: the CLL cell limbo

F. Rodríguez-Gómez, O. Cuevas, J. Anguita, P. Muñoz

Impact of Donor Characteristics and HLA Matching on Survival of Chinese Patients with Hematologic Malignancies Undergoing Unrelated Hematopoietic Stem.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Sabina Kersting, Leo F. Verdonck

Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Gita Thanarajasingam, Haesook T. Kim,

Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions Darius Sairafi, Mats Remberger, Michael.

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

Volume 70, Pages S21-S25 (December 2006)

Steven J. Chadban, Natalie D. Staplin Kidney International

Comorbidity and confounding in end-stage renal disease

Volume 70, Issue 11, Pages (December 2006)

Volume 70, Issue 12, Pages (December 2006)

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence Keshav.

Effects of Conditioning Regimens and T Cell Depletion in Hematopoietic Cell Transplantation for Primary Immune Deficiency Brandon M. Triplett, Chong.

Volume 149, Issue 6, Pages (November 2015)

Correlation between time to positivity of blood cultures with clinical presentation and outcomes in patients with Klebsiella pneumoniae bacteraemia: prospective.

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

HLA-Mismatched, Noninherited Maternal Antigen–Matched Unrelated Cord Blood Transplantations Have Superior Survival: How HLA Typing the Cord Blood Donor's.

by Michael R. DeBaun, and Ellen Wright Clayton

This Month in AJKD American Journal of Kidney Diseases

Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.

Charles A. Herzog Kidney International

Mammen Chandy Biology of Blood and Marrow Transplantation

Treatment versus Transplant for Challenging Hematologic Disorders

Sickle cells and sickle trait in thrombosis

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Mary Eapen Biology of Blood and Marrow Transplantation

Rituximab immunotherapy: it’s getting personal

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

A binding relationship with thrombin

Quiz page December 2003 American Journal of Kidney Diseases

by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio

Initial treatment of CLL: integrating biology and functional status

Balancing bleeding in brain metastases

Cold agglutinin disease

Presentation transcript:

Stage C or not stage C…? by Claire Dearden Blood Volume 116(23):4735-4736 December 2, 2010 ©2010 by American Society of Hematology

Survival of patients with CLL by Binet stage of disease. Survival of patients with CLL by Binet stage of disease. Stage C disease is further divided by stage C ‘infiltrative’ and C ‘immune’ showing inferior outcome for the stage C ‘infiltrative.’ See the complete figure in the article beginning on page 4771. Claire Dearden Blood 2010;116:4735-4736 ©2010 by American Society of Hematology